Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,148.00    22.00 (1.03%)
Bid:
2,144.00
Ask:
2,154.00
Spread: 10.00 (0.466%)
Market Cap: £1.43b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Pre-Close Trading Update

9 Jul 2009 07:00

RNS Number : 3707V
Genus PLC
09 July 2009
 



For immediate release 9 July 2009

GENUS plc

("Genus" or "the Company")

Pre-Close Trading Update

Genus, a world leading animal genetics company, today provides the following update on trading for the six months to 30th June 2009.

Despite tough short-term market conditions driven by the general economic slowdown, Genus continues to expect to report a strong increase in profits for the year to 30 June 2009, with the results benefiting from the international diversity of the Group's operations and the weakness of sterling.

Whilst market conditions for Genus' customers have remained challenging, trading for Genus has been broadly in-line with the Board's expectations during the final quarter. The one exception was a further weakness in the North American dairy market caused by exceptionally low milk prices. Nevertheless, Genus continues to expect that adjusted profit before tax* for the full year will be in line with market expectations. 

For further information contact:-

Genus plc Tel: 01256 345970

Richard Wood, Chief Executive

John Worby, Finance Director

Buchanan Communications Tel: 0207 466 5000

Charles Ryland/Isabel Podda/Jennie Spivey

This announcement is available on the Genus website, www.genusplc.com

*Adjusted Profit Before Tax represents profits before tax excluding non cash items relating to the fair value movement on biological assets, amortisation of acquired intangibles, share based payments and exceptional items. This measure is used to demonstrate underlying performance and in the current year is being amended to exclude only that part of amortisation relating to acquired intangibles. This amendment in accounting treatment amounts to a net reduction in adjusted profit before tax of £0.6m (2008:£0.1m). 

About Genus

Genus creates advances to animal breeding through biotechnology and sells added value products for livestock farming and food producers. Its non-Genetically Modified Organism (GMO) technology is applicable across all livestock species but is only commercialised by Genus in the bovine and porcine farming sectors.

Genus' worldwide sales are made in seventy countries under the trademarks "ABS" (dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production. Customers' animals produce offspring with greater production efficiency, milk and meat output and quality and use these to supply the global dairy and meat supply chain. 

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and the Group's global production and distribution network.

Headquartered in BasingstokeEngland, Genus companies operate in 30 countries on six continents, with research laboratories located in MadisonUSA.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTEAKXPESSNEFE
Date   Source Headline
10th Oct 20134:35 pmRNSAnnual Report & Annual General Meeting
3rd Oct 20132:00 pmRNSAdditional Listing
2nd Oct 20135:00 pmRNSTotal Voting Rights
27th Sep 20136:19 pmRNSDirector/PDMR Shareholding
23rd Sep 20137:00 amRNSGenus to Acquire Génétiporc
3rd Sep 20133:04 pmRNSCorrection of Record Date
3rd Sep 20137:00 amRNSPreliminary Results
31st Jul 20133:00 pmRNSBlocklisting Interim Review
25th Jul 201310:14 amRNSCompany Secretary Appointment
18th Jul 20139:00 amRNSHolding(s) in Company
11th Jun 20135:07 pmRNSHolding(s) in Company
4th Jun 20139:10 amRNSHolding(s) in Company
31st May 20132:00 pmRNSTotal Voting Rights
23rd May 20138:22 amRNSDirector/PDMR Shareholding
21st May 20134:56 pmRNSHolding(s) in Company
30th Apr 20137:00 amRNSInterim Management Statement
8th Apr 20136:09 pmRNSHolding(s) in Company
8th Apr 201310:27 amRNSHolding(s) in Company
28th Mar 20134:13 pmRNSHolding(s) in Company
28th Mar 20133:51 pmRNSTotal Voting Rights
21st Mar 20132:00 pmRNSHolding(s) in Company
11th Mar 20134:07 pmRNSDirector/PDMR Shareholding
4th Mar 20132:00 pmRNSHolding(s) in Company
28th Feb 20132:30 pmRNSTotal Voting Rights
28th Feb 20132:00 pmRNSDirector/PDMR Shareholding
25th Feb 20134:21 pmRNSDirector/PDMR Shareholding
25th Feb 20137:00 amRNSInterim Results
25th Feb 20137:00 amRNSSecond New Joint Venture in China
4th Feb 201310:00 amRNSHolding(s) in Company
31st Jan 20132:00 pmRNSBlocklisting Interim Review
31st Jan 20132:00 pmRNSTotal Voting Rights
8th Jan 20132:00 pmRNSHolding(s) in Company
13th Dec 20127:00 amRNSDirectorate Change
7th Dec 201210:00 amRNSDirector/PDMR Shareholding
30th Nov 20122:00 pmRNSTotal Voting Rights
14th Nov 201210:00 amRNSHolding(s) in Company
8th Nov 20123:30 pmRNSAGM Statement
8th Nov 20127:00 amRNSAGM and Interim Management Statement
31st Oct 20122:03 pmRNSTotal Voting Rights
26th Oct 201210:00 amRNSHolding(s) in Company
17th Oct 201210:00 amRNSHolding(s) in Company
9th Oct 20122:00 pmRNSAnnual Report and details of AGM
28th Sep 20122:00 pmRNSTotal Voting Rights
27th Sep 201211:00 amRNSAdditional Listing
27th Sep 20128:00 amRNSHolding(s) in Company
26th Sep 20124:01 pmRNSDirector/PDMR Shareholding
4th Sep 20127:00 amRNSPreliminary Results
31st Aug 20122:00 pmRNSTotal Voting Rights
23rd Aug 20126:18 pmRNSHolding(s) in Company
20th Aug 20127:00 amRNSAppointment of Joint Broker

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.